A Chat with Bernie Iliakis of CorneaGen - Takeaways - MDSpire

A Chat with Bernie Iliakis of CorneaGen

Bernie Iliakis, president and CEO of CorneaGen, discusses the growing momentum of CTAK to treat keratoconus, how the company is meeting the growing demand for DMEK and DSAEK tissue processing, and more.

  • November 1, 2025

  • 4 min

Share

  • 1

    CorneaGen launched Corneal Tissue Addition for Keratoplasty (CTAK) in June 2024, improving sight for keratoconus patients.

  • 2

    CTAK utilizes custom, gamma-irradiated, non-immunogenic corneal tissue inlays tailored to individual patient needs.

  • 3

    CorneaGen has performed over 1,000 CTAK procedures in the U.S. and expanded its reach internationally by September 2025.

  • 4

    The organization pioneered innovations in corneal transplantation, including the use of amphotericin B in storage media.

  • 5

    Bernie Iliakis, CorneaGen's CEO, emphasizes the importance of personal connections in corneal donation and transplantation.

Original Source(s)

A Chat with Bernie Iliakis of CorneaGen

  • November 1, 2025

Related Content

The Latest in Keratoconus Treatment

While corneal transplantation allows for excellent vision, it also exposes the keratoconus patient to significant risks. Recent innovations in keratoconus management have developed to greatly improve quality of life for these patients.

Corneal Crosslinking Reimbursement<br>In Its Tenth Year

Providing crosslinking procedures in an ophthalmology practice is not for the faint of heart. Ultimately, despite its clinical importance, offering crosslinking remains financially challenging for many practices.

Personalizing Corneal Cross-Linking

How tailored approaches to CXL are transforming how we treat keratoconus and other corneal ectasias